Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

US11034757B2 · kind B2 · utility

Assignees

• Biomed Valley Discoveries, Inc. · US
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Saurabh Saha · Wellesley, US
• Xiaoyan Zhang · Lexington, US
• Dimiter S. Dimitrov · Frederick, US
• Zhongyu Zhu · Frederick, US
• Brad St. Croix · Frederick, US
• Enrique Zudaire · Germantown, US

Key dates

• Filing date: Jun 9, 2015
• Grant date: Jun 15, 2021
• Expiry date: Sep 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including bevacizumab and at least one additional therapeutic agent; or a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of a COX-2 inhibitor (COXIB), a non-steroidal anti-inflammatory drug (NSAID), a prostaglandin E2 (PGE2) synthase inhibitor, and combinations thereof. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.